NO20004431L - Glysintransportinhibitorer - Google Patents

Glysintransportinhibitorer

Info

Publication number
NO20004431L
NO20004431L NO20004431A NO20004431A NO20004431L NO 20004431 L NO20004431 L NO 20004431L NO 20004431 A NO20004431 A NO 20004431A NO 20004431 A NO20004431 A NO 20004431A NO 20004431 L NO20004431 L NO 20004431L
Authority
NO
Norway
Prior art keywords
epsi
epilepsy
piperazinyl
piperidinyl
fluorophenyl
Prior art date
Application number
NO20004431A
Other languages
English (en)
Other versions
NO20004431D0 (no
Inventor
Walter Herman Maria Lou Luyten
Frans Eduard Janssens
Ludo Edmond Josephine Kennis
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20004431D0 publication Critical patent/NO20004431D0/no
Publication of NO20004431L publication Critical patent/NO20004431L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

Den foreliggende oppfinnelse vedrører anvendelsen av glysintransportinhiberende 4,4-bis (4-fluorfenyl)butyl]-1-(piperazinyl og piperidinyl)-derivater ved fremstillingen av medikamenter for å behandle forstyrrelser i det sentrale og perifere nervesystem, spesielt psykoser, smerte, epil-epsi, nevrodegenerative sykdommer (Alzheimers sykdom),. slag, hodetraume, multippel sklerose og lignende. Opp-finnelsen omfatter videre nye forbindelser, deres frem-stilling og deres farmasøytisk former.
NO20004431A 1998-03-06 2000-09-05 Glysintransportinhibitorer NO20004431L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98200701 1998-03-06
PCT/EP1999/001309 WO1999044596A2 (en) 1998-03-06 1999-02-26 Glycine transport inhibitors

Publications (2)

Publication Number Publication Date
NO20004431D0 NO20004431D0 (no) 2000-09-05
NO20004431L true NO20004431L (no) 2000-10-30

Family

ID=8233444

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004431A NO20004431L (no) 1998-03-06 2000-09-05 Glysintransportinhibitorer

Country Status (17)

Country Link
EP (1) EP1059922A2 (no)
JP (1) JP2002505277A (no)
KR (1) KR20010032968A (no)
CN (1) CN1292698A (no)
AU (1) AU3408999A (no)
BG (1) BG104685A (no)
BR (1) BR9907951A (no)
CA (1) CA2322164A1 (no)
EE (1) EE200000482A (no)
HR (1) HRP20000523A2 (no)
HU (1) HUP0101048A2 (no)
IL (1) IL138228A0 (no)
NO (1) NO20004431L (no)
PL (1) PL343435A1 (no)
SK (1) SK13082000A3 (no)
TR (1) TR200002567T2 (no)
WO (1) WO1999044596A2 (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2215670T3 (es) 1999-06-28 2004-10-16 Janssen Pharmaceutica N.V. Inhibidores de la replicacion del virus sincitial respiratorio.
UA73749C2 (en) * 1999-11-01 2005-09-15 Diarylenines
EP1296950A2 (en) * 2000-04-20 2003-04-02 NPS Allelix Corp. Aminopiperidines for use as glyt-1 inhibitors
DE10040016A1 (de) * 2000-08-16 2002-02-28 Boehringer Ingelheim Pharma Neue beta-Amyloid Inhibitoren, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
WO2002019967A2 (en) 2000-09-08 2002-03-14 Gliatech, Inc. Substituted hydrazine derivatives
CA2422044A1 (en) 2000-09-14 2002-03-21 Gliatech, Inc. Nitrogen-containing compounds and their use as glycine transport inhibitors
AR032653A1 (es) 2001-02-09 2003-11-19 Telik Inc Inhibidores heterociclicos del trasportador de glicina 2 composiciones farmaceuticas, uso y metodos.
US7030150B2 (en) 2001-05-11 2006-04-18 Trimeris, Inc. Benzimidazole compounds and antiviral uses thereof
CN1874777B (zh) 2003-09-09 2012-07-04 弗·哈夫曼-拉罗切有限公司 作为甘氨酸摄取抑制剂用于治疗精神病的1-(2-氨基-苯甲酰基)-哌嗪衍生物
WO2005023261A1 (en) 2003-09-09 2005-03-17 F. Hoffmann-La Roche Ag 1-benzoyl-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
WO2005058885A2 (en) * 2003-12-18 2005-06-30 Glaxo Group Limited Piperidine derivatives and their use as glycine transporter inhibitors
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
PL1828154T3 (pl) 2004-12-09 2009-10-30 Hoffmann La Roche Pochodne fenylopiperazynometanonu
ATE457989T1 (de) * 2004-12-15 2010-03-15 Hoffmann La Roche Bi- und trizyklische substituierte phenyl- methanone als inhibitoren von glycin-i (glyt-1)- transportern zur behandlung der alzheimer- krankheit
PE20061156A1 (es) 2004-12-23 2006-12-16 Glaxo Group Ltd Derivados de benzamida como agentes inhibidores del transportador de glicina
GB0428233D0 (en) * 2004-12-23 2005-01-26 Glaxo Group Ltd Compounds
US7485637B2 (en) 2005-01-04 2009-02-03 Hoffmann-La Roche Inc. Benzoyl-tetrahydropiperidine derivatives
MX2007008190A (es) * 2005-01-06 2007-08-07 Hoffmann La Roche Fenil metanonas sustituidas con sulfanilo como inhibidores del transportador de glicina 1 (glyt-1) para el tratamiento de trastornos neurologicos y neuropsiquiatricos.
BRPI0519794A2 (pt) 2005-01-07 2009-03-17 Hoffmann La Roche derivados de [4-(heteroaril)piperazin-1-il]-(fenil 2,5-substituìdo)metanona como inibidores de transportador de glicina 1 (glyt-1) para o tratamento de distúrbios neurológicos e neuropsiquiátricos
ATE435650T1 (de) 2005-01-18 2009-07-15 Hoffmann La Roche 2,5-disubstituierte phenylmethanonderivative als glycintransporter-1-inhibitoren (glyt-1) zur behandlung von neurologischen und neuropsychiatrischen störungen
ATE447572T1 (de) 2005-01-26 2009-11-15 Hoffmann La Roche Phenylmethanonderivate und ihre verwendung als glycin-transporter-1-hemmer
DE602006010665D1 (en) 2005-02-07 2010-01-07 Hoffmann La Roche Heterocyclsche substituierte phenylmethanone als inhibitoren des glycintransporters 1
CN100341871C (zh) * 2005-06-03 2007-10-10 复旦大学 含哌啶结构的有机硫化合物,制备方法和应用
WO2007110449A1 (en) 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
US8791264B2 (en) 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
WO2007118854A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and the use thereof
ES2433118T3 (es) * 2006-11-01 2013-12-09 Purdue Pharma Lp Compuestos de fenilpropionamida y uso de los mismos
FR2910321B1 (fr) 2006-12-21 2009-07-10 Galderma Res & Dev S N C Snc Gel creme comprenant au moins un retinoide et du peroxyde de benzole
FR2910320B1 (fr) * 2006-12-21 2009-02-13 Galderma Res & Dev S N C Snc Emulsion comprenant au moins un retinoide et du peroxyde de benzole
WO2008124118A1 (en) 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
WO2009040659A2 (en) 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
JP2011506441A (ja) * 2007-12-12 2011-03-03 アムジエン・インコーポレーテツド グリシン輸送体−1阻害薬

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1140119A (en) * 1978-04-03 1983-01-25 Joseph Torremans N-heterocyclyl-4-piperidinamines
US4219559A (en) * 1979-01-10 1980-08-26 Janssen Pharmaceutica N.V. N-Heterocyclyl-4-piperidinamines
US4695575A (en) * 1984-11-13 1987-09-22 Janssen Pharmaceutica, N.V. 4-[(bicycle heterocyclyl)-methyl and -hetero]-piperidines
PH23995A (en) * 1984-01-09 1990-02-09 Janssen Pharmaceutica Nv 4((bicycle heterocyclyl)-methyl and hetero)piperidines
WO1999025353A1 (en) * 1997-11-13 1999-05-27 Merck Sharp & Dohme Limited Therapeutic uses of triazolo-pyridazine derivatives

Also Published As

Publication number Publication date
TR200002567T2 (tr) 2000-11-21
BR9907951A (pt) 2001-01-30
WO1999044596A3 (en) 2000-02-17
KR20010032968A (ko) 2001-04-25
AU3408999A (en) 1999-09-20
JP2002505277A (ja) 2002-02-19
WO1999044596A2 (en) 1999-09-10
SK13082000A3 (sk) 2001-03-12
CN1292698A (zh) 2001-04-25
HUP0101048A2 (hu) 2001-10-28
IL138228A0 (en) 2001-10-31
HRP20000523A2 (en) 2001-02-28
BG104685A (en) 2001-04-30
CA2322164A1 (en) 1999-09-10
EE200000482A (et) 2002-02-15
PL343435A1 (en) 2001-08-13
NO20004431D0 (no) 2000-09-05
EP1059922A2 (en) 2000-12-20

Similar Documents

Publication Publication Date Title
NO20004431L (no) Glysintransportinhibitorer
NO20004432L (no) Glysintransportinhibitorer
CA2501799A1 (en) Pyrazole compounds for treatment of neurodegenerative disorders
MXPA05002420A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos.
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
DE60037139D1 (de) Polyhydroxylierte aromatischen verbindungen für die behandlung von amyloidosis und alpha-synuclein fibril krankheiten
PT1259489E (pt) Compostos azapoliciclicos condensados con arilo.
AP2004002952A0 (en) N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds.
PT1427708E (pt) Derivados amino-ftalazinona activos como inibidors de cinase, processo para a sua preparação e composições farmacêuticas contendo-os
MXPA04003245A (es) Hidroxipropilaminas.
WO2001053457A3 (en) Vaccines against neurodegenerative disorders
ATE367387T1 (de) Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden
DE59900222D1 (de) Verwendung von hyperforin und hyperforinhaltigen extrakten zur behandlung und prophylaxe von demenzerkrankungen
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
DE60231054D1 (de) Piperidinderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzung zur behandlung von alzheimer-krankheit, die diese derivate enthält
GR3032531T3 (en) Use of efaxoran and its derivatives for the production of drugs for treating neurodegenerative diseases
ATE294794T1 (de) N-heterocyclylhydrazide als neurotrophe mittel
BR0116724A (pt) Composto, método de tratamento de um distúrbio neurológico ou de uma doença neurodegenerativa, método de tratamento de dor, composição farmacêutica, uso de um composto, e, processos para a preparação e para a sìntese de um composto
NO993126D0 (no) Anvendelse av benzoylalkyl-1,2,3,6-tetrahydropyridiner
ATE347893T1 (de) Triazepin-derivate als neurotrope mittel
DE602004019133D1 (de) Verwendung von 1,2-diazadibenzoäe,hüazulenen zur herstellung von pharmazeutischen formulierungen für die behandlung und prävention von erkrankungen und störungen des zentralen nervensystems
DE602004008796D1 (de) VERWENDUNG VON 1,3-DIAZADIBENZOÄe,hÜ AZULENEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN FORMULIERUNGEN FÜR DIE BEHANDLUNG UND PRÄVENTION VON ERKRANKUNGEN UND STÖRUNGEN DES ZENTRALEN NERVENSYSTEMS
EA200500382A1 (ru) Соединения тиазола для лечения нейродегенеративных расстройств

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application